95 related articles for article (PubMed ID: 2502594)
1. A new way to induce oestrogen-deficiency osteopaenia in the rat: comparison of the effects of surgical ovariectomy and administration of the LHRH agonist buserelin on bone resorption and composition.
Goulding A; Gold E
J Endocrinol; 1989 May; 121(2):293-8. PubMed ID: 2502594
[TBL] [Abstract][Full Text] [Related]
2. Norethindrone acetate only partially protects the skeleton of rats treated with the LHRH agonist buserelin from oestrogen-deficiency osteopaenia.
Goulding A; Gold E
J Endocrinol; 1993 Apr; 137(1):27-33. PubMed ID: 8492074
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen in the rat prevents estrogen-deficiency bone loss elicited with the LHRH agonist buserelin.
Goulding A; Gold E; Feng W
Bone Miner; 1992 Aug; 18(2):143-52. PubMed ID: 1525595
[TBL] [Abstract][Full Text] [Related]
4. Preventive effects of clomiphene citrate on estrogen-deficiency osteopenia elicited by LHRH agonist administration in the rat.
Goulding A; Fisher L
J Bone Miner Res; 1991 Nov; 6(11):1177-81. PubMed ID: 1805541
[TBL] [Abstract][Full Text] [Related]
5. Buserelin-mediated osteoporosis: effects of restoring estrogen on bone resorption and whole body calcium content in the rat.
Goulding A; Gold E
Calcif Tissue Int; 1990 Jan; 46(1):14-9. PubMed ID: 2104770
[TBL] [Abstract][Full Text] [Related]
6. 17 beta-estradiol protects rats from osteopenia associated with administration of the luteinising hormone releasing hormone (LHRH) agonist, buserelin.
Goulding A; Fisher L
Bone Miner; 1991 Apr; 13(1):47-53. PubMed ID: 1905969
[TBL] [Abstract][Full Text] [Related]
7. Flutamide-mediated androgen blockade evokes osteopenia in the female rat.
Goulding A; Gold E
J Bone Miner Res; 1993 Jun; 8(6):763-9. PubMed ID: 8328318
[TBL] [Abstract][Full Text] [Related]
8. Effects of chronic prednisolone treatment on bone resorption and bone composition in intact and ovariectomized rats and in ovariectomized rats receiving beta-estradiol.
Goulding A; Gold E
Endocrinology; 1988 Feb; 122(2):482-7. PubMed ID: 3338411
[TBL] [Abstract][Full Text] [Related]
9. Effects of chronic treatment with oestrogen, an oestrogen antagonist and a potent luteinizing hormone releasing hormone agonist analogue on pituitary responsiveness to luteinizing hormone releasing hormone in the rat.
Hall JM; Whitehead SA
J Endocrinol; 1983 Sep; 98(3):313-21. PubMed ID: 6413634
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors.
Bakker GH; Setyono-Han B; Henkelman MS; de Jong FH; Lamberts SW; van der Schoot P; Klijn JG
Cancer Treat Rep; 1987 Nov; 71(11):1021-7. PubMed ID: 3119199
[TBL] [Abstract][Full Text] [Related]
11. Effect of administration and subsequent cessation of buserelin on cancellous bone of female rats.
Tobias JH; Chambers TJ; Gallagher A
J Bone Miner Res; 1994 Dec; 9(12):1919-25. PubMed ID: 7872057
[TBL] [Abstract][Full Text] [Related]
12. The rate of cancellous bone formation falls immediately after ovariectomy in the rat.
Lean JM; Chow JW; Chambers TJ
J Endocrinol; 1994 Jul; 142(1):119-25. PubMed ID: 7964270
[TBL] [Abstract][Full Text] [Related]
13. The mechanisms of antitumor effects of luteinizing hormone-releasing hormone agonist (buserelin) in 7, 12-dimethylbenz(a)anthracene-induced rat mammary cancer.
Koibuchi Y; Sugamata N; Iino Y; Yokoe T; Andoh T; Maemura M; Takei H; Horiguchi J; Matsumoto H; Morishita Y
Int J Mol Med; 1999 Aug; 4(2):145-8. PubMed ID: 10402480
[TBL] [Abstract][Full Text] [Related]
14. Blockade of LH and FSH secretion by LH-releasing hormone, by the LH-releasing hormone analogue, buserelin, and by combined treatment with LH-releasing hormone and oestradiol benzoate.
Schuiling GA; Pols-Valkhof N; van der Schaaf-Verdonk GC; Koiter TR
J Endocrinol; 1984 Dec; 103(3):301-9. PubMed ID: 6438265
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen and norethisterone: effects on plasma cholesterol and total body calcium content in the estrogen-deficient rat.
Gold E; Stapley S; Goulding A
Horm Metab Res; 1994 Feb; 26(2):100-3. PubMed ID: 8200611
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced prevention of gastrectomy- and ovariectomy-induced osteopaenia in the young female rat.
Andersson N; Surve VV; Lehto-Axtelius D; Ohlsson C; Håkanson R; Andersson K; Ryberg B
J Endocrinol; 2002 Dec; 175(3):695-703. PubMed ID: 12475380
[TBL] [Abstract][Full Text] [Related]
17. Influence of the gonad on the degree of suppression induced by an LHRH agonist implant in the marmoset monkey.
Lunn SF; Cowen GM; Morris KD; Fraser HM
J Endocrinol; 1992 Feb; 132(2):217-24. PubMed ID: 1541921
[TBL] [Abstract][Full Text] [Related]
18. The prolonged action of the LHRH agonist buserelin (HOE 766) may be due to prolonged binding to the LHRH receptor.
Koiter TR; Denef C; Andries M; Moes H; Schuiling GA
Life Sci; 1986 Aug; 39(5):443-52. PubMed ID: 3016440
[TBL] [Abstract][Full Text] [Related]
19. Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment.
Kimoto A; Tanaka M; Nozaki K; Mori M; Fukushima S; Mori H; Shiroya T; Nakamura T
Bone; 2013 Jul; 55(1):189-97. PubMed ID: 23486179
[TBL] [Abstract][Full Text] [Related]
20. The effects of hyaluronan on bone resorption and bone mineral density in a rat model of estrogen deficiency-induced osteopenia.
Stancíková M; Svík K; Istok R; Rovenský J; Velebný V
Int J Tissue React; 2004; 26(1-2):9-16. PubMed ID: 15573687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
